<DOC>
	<DOCNO>NCT02652962</DOCNO>
	<brief_summary>The purpose study determine safety tolerability Gelesis200 .</brief_summary>
	<brief_title>Gelesis200 Safety Tolerability Study Effects Glycemic Appetite Parameters</brief_title>
	<detailed_description>This cross-over within parallel design . Parallel group receive Gelesis200 either 2 time 3 time one day meal . Within parallel group , subject cross-over 4 arm : A ) Gelesis200 10 min meal , B ) Gelesis200 30 min meal , C ) Placebo 10 min meal , D ) Placebo 30 min meal . Postprandial glucose , insulin subjective appetite rating also measure .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . Male , nonsmoker ( use tobacco product within 6 month prior screen ) , ≥ 22 ≤ 65 year age , BMI ≥ 27.0 &lt; 35.0 kg/m2 . 2 . Healthy define : 1. absence clinically significant illness surgery within 12 week prior administration . Subjects vomit within 24 hour preadministration carefully evaluate upcoming illness/disease . Inclusion preadministration discretion Qualified Investigator . 2. absence clinically significant history neurological , endocrine , cardiovascular , pulmonary , hematological , immunologic , psychiatric , gastrointestinal , renal , hepatic , metabolic disease , include , limited pancreatitis , hepatitis B C , HIV , swallow disorder , gastroesophageal reflux disease ( least 1 episode per week ) . 3. absence clinically significant history gastric peptic ulcer , small bowel resection ( except relate appendectomy ) , intestinal stricture ( e.g. , Crohn 's disease ) , intestinal obstruction high risk intestinal obstruction include suspect small bowel adhesion . 4. absence clinically significant history know presence esophageal anatomic abnormality ( e.g. , web , diverticuli , ring ) , gastroparesis , malabsorption . 5. absence history gastric bypass , gastric surgery intragastric balloon . 6. absence history angina , coronary bypass , myocardial infarction within 6 month prior administration . 7. absence history abdominal radiation treatment . 8. absence history cancer within past 5 year , except adequatelytreated localized basal cell skin cancer . 3 . Capable consent . 4 . Fasting plasma glucose ≥ 90 &lt; 126 mg/dL ( equivalent ≥ 5.0 &lt; 7.0 mmol/L ) screening . Notwithstanding low limit 90 mg/dL ( equivalent 5.0 mmol/L ) , subject high fast plasma glucose prioritize , effort make include subject fast plasma glucose ≥ 100 mg/dL ( equivalent ≥ 5.6 mmol/L ) cohort . Exclusion criteria 1 . Any clinically significant abnormality abnormal laboratory test result find medical screening positive test hepatitis B , hepatitis C , HIV find medical screening . 2 . Positive urine drug screen screen . 3 . History allergic reaction carboxymethylcellulose , citric acid , modify cellulose , microcrystalline cellulose , maltodextrin , gelatin , titanium dioxide , related substance . 4 . Any reason , opinion Qualified Investigator , would prevent subject participate study . 5 . Clinically significant electrocardiogram ( ECG ) abnormalities vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . 6 . History significant alcohol abuse within one year prior screen regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) . 7 . History significant drug abuse within one year prior screen use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] , crack ) within 1 year prior screen . 8 . Participation clinical trial involve administration investigational market drug device within 30 day ( 90 day biologics ) prior first administration concomitant participation investigational study involve drug device . 9 . Use medication topical product without significant systemic absorption : 1. prescription medication within 30 day prior first administration ; 2. overthecounter product include natural health product ( e.g. , food supplement herbal supplement ) within 7 day prior first administration , exception occasional use acetaminophen ( 2 g daily ) ; 3. depot injection implant drug within 3 month prior first administration . 10 . Donation plasma within 7 day prior first administration . Donation loss blood ( exclude volume drawn screen ) 50 mL 499 mL blood within 30 day , 499 mL within 56 day prior first administration . 11 . Hemoglobin &lt; 140 g/L hematocrit &lt; 0.37 L/L screening . 12 . Glycosylated hemoglobin ( HbA1c ≥ 6.5 % equivalent ≥ 48 mmol/mol ) . 13 . Serum lowdensity lipoprotein cholesterol ≥ 190 mg/dL ( ≥ 4.93 mmol/L ) . 14 . Serum triglycerides ≥ 500 mg/dL ( ≥ 5.65 mmol/L ) . 15 . Anticipating surgical intervention study .</criteria>
	<gender>Male</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>